Executive Interviews
The ‘Unused Billion’: How Points4Purpose is Disrupting the Flatlining Loyalty Market
The loyalty industry is plagued by “sameness,” leaving billions in value dormant. Ivan Schwartz’s Points4Purpose is disrupting this flatlining market by turning rewards into a liquid currency for rent, bills, and over 1.8 million charities.
1,000km, sustainable, efficient , no onboard pilot: How ‘Gap Drone ’ is rewriting the rules of remote logistics
Can autonomous drones solve Australia’s “tyranny of distance”? GAP Drone CEO Liesl Haris thinks so. With the launch of ATLAS—an autonomous transport logistics aircraft system—the company is bypassing traditional infrastructure to deliver 50kg payloads over 1,000km. Dubbed the “Uber of airfreight,” GAP Drone is tackling the “too hard basket” of remote logistics, partnering with Australia Post to provide First Nations communities and regional hubs with reliable, low-cost access to medicine, food, and economic opportunity. By operating within current regulatory frameworks and utilising a “no-runway” launch model, GAP Drone is transforming air freight from an expensive luxury into a scalable utility.
Precision Care, Zero Clicks: Why the Future of the NDIS is Voice-First
Carelogix is solving the healthcare burnout crisis by replacing manual typing with a sophisticated AI “care co-pilot.” By reclaiming nearly half of a caregiver’s day, the platform offers a significant value inflection point for providers and investors in the trillion-dollar care economy.
Arterial Alchemy: Turning the ‘Ticking Time Bomb’ of Heart Disease into Excretable Waste
Current heart medications thin the “grease” in our blood, but Atherid Therapeutics is building the first biological clearing agent to actually scrub the pipes clean. With human trials slated for 2027, the goal is to make heart attacks a preventable and reversible condition.
Breaking the ‘Bird’s Nest’: How Amplia Therapeutics is Piercing the Shield of Pancreatic Cancer
Led by award-winning drug developer Dr. Chris Burns, Amplia Therapeutics (ASX: ATX) is taking a “one-two punch” approach to one of medicine’s deadliest challenges. By utilizing their lead asset, narmafotinib, to dismantle the protective “bird’s nest” of fibrotic tissue surrounding pancreatic tumors, Amplia has achieved a 35% interim response rate in Phase 2a trials. With FDA Fast Track status and critical survival data expected in 2026, the company is rapidly approaching a major commercial and clinical rerate.
The Better Pill to Swallow: Solving the $60B Drug Delivery Problem with AI
While most biotechs hunt for new molecules, BCS2 is fixing the ones we already have. Founder Stuart Gunzburg explains how his AI-powered platform transforms “insoluble” blockbuster drugs into rapid-acting sprays and films, creating a de-risked, high-speed pathway to market for a $60 billion opportunity.
The Silent Trigger: How Biotome is Dismantling the World’s Fourth Deadliest Cancer
Biotome is transforming gastric cancer detection through precision immunology. Their flagship test Helitope uses peptide augmentation to target specific bacterial markers, delivering 10 times greater sensitivity and 95% accuracy compared to traditional diagnostic tests.
The Endocannabinoid Entrepreneurs: Inside Medigrowth’s Mission to Mainstream Plant-Based Medicine
Medigrowth is transforming the Australian cannabis landscape from a “wild west” into a clinically-led biotech powerhouse. Led by founders Adam Guskich and Todd McClellan, the company is leveraging university-led research to target a multi-billion dollar unmet need in chronic conditions including pain and mental health.
Vision Via Sound for the Blind: Can a Silicon Valley Veteran Deliver the Solution to a $2B NDIS Problem?
Serial entrepreneur Robert Yearsley is trading pixels for perception with ARIA Research, a Sydney-based deep-tech company using “augmented reality in audio” to help the blind perceive the world. By bypassing traditional bionics in favour of real-time 3D soundscapes, ARIA is tackling a multi-billion dollar unmet need in the global disability sector and redefining what it means to “see” without eyesight.
Backed By Leading Investment Groups and Family Offices
